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Abstract
Background/aims: Liver sinusoidal endothelial cells (SECs), hepatic stellate cells (HSCs) and Kupffer cells (KCs) are
involved in the development of liver fibrosis and represent a potential therapeutic target. The therapeutic effects on
liver fibrosis of sorafenib, a multiple tyrosine kinase inhibitor, and gadolinium chloride (GdCl3), which depletes KCs,
were evaluated in rats.
Methods: Liver fibrosis was induced in rats with dimethylnitrosamine, and the effects of sorafenib and/or GdCl3 in
these rats were monitored. Interactions among ECs, HSCs and KCs were assessed by laser confocal microscopy.
Results: The combination of sorafenib and GdCl3, but not each agent alone, attenuated liver fibrosis and
significantly reduced liver function and hydroxyproline (Hyp). Sorafenib significantly inhibited the expression of
angiogenesis-associated cell markers and cytokines, including CD31, von Willebrand factor (vWF), and vascular endothelial
growth factor, whereas GdCl3 suppressed macrophage-related cell markers and cytokines, including CD68, tumor necrosis
factor-α, interleukin-1β, and CCL2. Laser confocal microscopy showed that sorafenib inhibited vWF expression and GdCl3
reduced CD68 staining. Sorafenib plus GdCl3 suppressed the interactions of HSCs, ECs and KCs.
Conclusion: Sorafenib plus GdCl3 can suppress collagen accumulation, suggesting that this combination may be a
potential therapeutic strategy in the treatment of liver fibrosis.
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Background
Liver fibrosis, as the final common endstage of most
chronic liver diseases, is triggered by chronic liver injury
caused by various etiologies including viral infection, chole-
stasis, metabolic diseases and alcohol abuse [1, 2]. Chronic
liver injury and the ensuing inflammatory responses result
in the activation of quiescent HSCs, which proliferate and
undergo phenotypical and morphological changes, subse-
quently turning into characteristic myofibroblasts with up-
regulated alpha-smooth muscle actin (α-SMA) expression
and ECM production [3–6]. Although the mechanisms
underlying the progression of hepatic fibrosis are fairly well
understood, safe and effective antifibrotic therapies are
needed for patients with chronic liver diseases [7].
Sorafenib is a multiple receptor tyrosine kinase inhibi-
tor targeting the Raf/ERK signaling pathways, as well as
receptor tyrosine kinases such as vascular endothelial
growth factor receptor (VEGFR) and platelet-derived
growth factor receptor (PDGFR)-β [8]. Sorafenib induces
apoptosis in various tumor cell lines and used to treat
patients with advanced hepatocellular carcinoma (HCC),
cholangiocellular carcinoma and portal pressure [9, 10].
Sorafenib was recently reported to suppress collagen ac-
cumulation in rats with liver fibrosis and portal hyper-
tension [11, 12]. Another study reported, however, that
sorafenib can induce liver damage, while reducing the
number of activated HSCs and intrahepatic vascular re-
sistance in cirrhotic livers [13].
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Macrophages play a key role in inflammation associ-
ated with liver fibrosis. The in vivo role of macrophages
has been assessed by depleting macrophage populations
with the macrophage apoptosis inducers gadolinium
chloride (GdCl3) and liposome-encapsulated dichloro-
methylene bisphosphonate (Cl2MBP). GdCl3 has been
found to reverse dimethylnitrosamine (DMN)-induced
rat liver fibrosis while increasing the expression of
matrix metalloproteinases (MMPs) by KCs [14, 15].
However, we found that GdCl3 did not reduce liver
fibrosis significantly because of its proinflammatory
effects on lung macrophages [16]. Taken together, these
findings indicate that liver fibrosis is a systematic disease
associated with specific microenvironments, including
interactions among HSCs, ECs and KCs. This study ana-
lyzed the effects of sorafenib plus GdCl3 on DMN-
induced liver fibrosis in rats.
Methods
Materials and chemicals
Sorafenib (Alexis Biochemicals, San Diego, CA, USA)
was dissolved in 1:1:6 mixture composed of Cremophor
EL (Sigma-Aldrich, St. Louis, MO, USA), ethanol and
water. GdCl3 was from Sigma-Aldrich (Catalog No.
203289) and DMN was from Wako (Osaka, Japan;
Catalog No. 149–05882). Sirius red was obtained from
Polysciences (Sigma-Aldrich; Catalog No. 365548) and
dissolved in saturated picric acid (Chroma, Munster,
Germany). SYBR Green Supermix was from Thermo
Fermentas (Glen Burnie, MD, USA), and prestained pro-
tein marker was purchased from New England Biolabs
(Beijing, China). All primary antibodies were from Santa
Cruz (Santa Cruz, CA, USA).
Ethics statement
All of the study protocols complied with the current
ethical considerations of Shanghai Public Health Clinical
Center’s Animal Ethic Committee and the procedural
and ethical guidelines of the Chinese Animal Protection
Act, which is in accordance with the National Research
Council criteria. All animal experiments and procedures
were reviewed and approved by the Institutional Animal
Care and Use Committee (IACUC) of Shanghai Public
Health Clinical Center and were performed in accord-
ance with the relevant guidelines and regulations.
Animal experiments
Wistar rats weighing 160–180 g were provided by the
Central Animal Care Facility of Shanghai Public Health
Clinical Center (Permission No: SCXK 2007–0006). All
animals were cared for humanely, in compliance with
the Chinese Animal Protection Act and National
Research Council criteria.
Rats were randomized into two groups, with 40 ani-
mals intraperitoneally injected with DMN (10 mg/kg
body weight) for three consecutive days per week for
4 weeks [17, 18], and ten control rats were injected with
equal volumes of physiological saline. At the beginning
of the third week, the DMN-treated rats were further
randomized into four groups, with ten each receiving so-
rafenib (1 mg/kg/day by gavage); GdCl3, at a dose of
7 mg/kg in isotonic saline [14] twice weekly for 2 weeks,
administered through the tail vein; sorafenib plus GdCl3;
or vehicle, as well as being continued on DMN for an-
other 2 weeks, as above. The dose of GdCl3 was set at
7 mg/kg, because this dose had no effect on liver en-
zyme activity but was reported to inhibit Kupffer cell
phagocytosis [19]. At the end of the fourth week, all the
rats were sacrificed under 2 % sodium pentobarbital
anesthesia, and all efforts were made to minimize suffer-
ing. Some of these samples were directly transferred to
buffered 10 % formaldehyde solution for paraffin embed-
ding, whereas the remainder were frozen in liquid nitro-
gen and stored for later analyses.
Serum biochemistry
Serum was prepared by centrifugation at 3000 rpm at
4 °C and stored at −80 °C. Serum concentrations of
alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), albumin (ALB) and total bilirubin were
measured by the Clinical Laboratory of Shanghai Public
Clinical Health Center.
Hydroxyproline determination
Hepatic hydroxyproline (Hyp) content was used as an
indirect measure of tissue collagen content. Hepatic hy-
droxyproline content was measured using a hydroxypro-
line detection kit (Jiancheng Institute of Biotechnology,
Nanjing, China) according to the manufacturer’s instruc-
tions. Hydroxyproline content was expressed as μg/gram
of liver wet weight.
Liver histology
Liver tissues from the right lobe of the liver of each rat
were fixed in 4 % buffered paraformaldehyde, and dehy-
drated in a graded alcohol series. Following the xylene
treatment, the specimens were embedded in paraffin
blocks, cut into 5 μm-thick sections and placed on glass
slides. The sections were stained with HE and Sirius red.
The area of Sirius red-positive staining was quantified
using a computer-aided image analysis software image-
pro plus version 6.1 (MediaCybernetics, USA).
Immunohistochemistry
After deparaffinization and dehydration, microwave anti-
gen retrieval was performed for 5 min, followed by perox-
idase quenching with 0.6 % H2O2 in phosphate-buffered
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saline (PBS) for 15 min. The sections were subsequently
blocked with 5 % bovine serum albumin (BSA) for 30 min
and incubated overnight at 4 °C with 1:100 dilutions of pri-
mary antibodies to vWF, CD68, and α-SMA. Negative con-
trol sections were treated identically, except for omission
of the primary antibodies. After washing in PBS, the sec-
tions were incubated with biotinylated secondary anti-
bodies for 30 min.
Protein extraction and western blot analysis
Protein was extracted and western blot analysis was per-
formed as described [18]. Briefly, aliquots of tissue ly-
sates containing 50 μg protein were electrophoresed on
10–12 % sodium dodecyl sulfate-polyacrylamide gels and
transferred to nitrocellulose membranes. The mem-
branes were blocked with 5 % BSA and incubated with
1:100 dilutions of antibodies overnight at 4 °C, followed
by incubation with horseradish peroxidase-conjugated
goat anti-mouse antibody (1:5000) and visualization by
enhanced chemiluminescence (Pierce, Rockford, IL,
USA) using Kodak films (Kodak, Rochester, NY, USA).
Quantitative real-time PCR
RNA isolation, reverse transcription, and RT-PCR were
performed as previously described [20]. Briefly, total RNA
was isolated from 50 mg flash-frozen liver tissue using
RNeasy-easy kit (Qiagen, Hilden, Germany, Cat: 74104),
followed by reverse transcription of 1 μg aliquots of RNA
(Fermentas). Quantitative polymerase chain reaction (PCR)
was performed on an ABI7700 Sequence detector (Applied
Biosystems, Rotkreuz, Switzerland using the primer se-
quences shown in Additional file 1: Table S1. The expres-
sion of each gene was normalized relative to that of 18S
rRNA using the delta–delta cycle threshold method.
Laser confocal microscopy
Liver samples were assessed grossly, immersed immedi-
ately in Tissue-Tek OCT, snap-frozen in liquid nitrogen;
and cut into 5 μm. The cryosections were stained se-
quentially with different combinations of antibodies,
resulting in tricolor labeling. Imaging results were ana-
lyzed using a Leica (Mannheim, Germany) DMIRBE
inverted stand and a Leica TCS2MP confocal system.
Statistical analysis
Each experiment was performed at least three times inde-
pendently. Results are expressed as mean ± S.D. All statis-
tical analyses were performed using SPSS software version
18.0. Differences between two groups were compared with
a two-tailed unpaired t test. Differences between multiple
groups were compared by one-way analysis of variance
with post hoc Tukey tests, with p < 0.05 considered statis-
tically significant.
Results
Effects of sorafenib plus GdCl3 on liver function
During drug intervention, two rats died in the 4 week
DMN group, and one in the GdCl3 group. Animal body,
liver, spleen weights were monitored during the formation
of liver fibrosis (Additional file 1: Table S2). Compared
with control rats, body, and liver weights decreased sig-
nificantly in the 4 week DMN group (p < 0.01), whereas
the spleen weight in the 4 week DMN rats increased sig-
nificantly (p < 0.01). the combination of sorafenib with
GdCl3 significantly increase liver weight (p < 0.05) and de-
crease spleen weight (p < 0.01) compared with 4 week
DMN rats.
Rats treated for 4 weeks with DMN developed hepatic
injury, as evidenced by significantly higher plasma concen-
trations of AST, ALT, and total bilirubin (TBil) and a sig-
nificantly lower concentration of ALB compared with
normal control rats (p < 0.01 each). While treatment with
either sorafenib or GdCl3 had no effect on these plasma
protein concentrations (Additional file 1: Table S3), the
combination of sorafenib with GdCl3 significantly amelio-
rated the increases in ALT, AST, and TBil, and the de-
crease in ALB (p < 0.05 or p < 0.01) indicating there were
synergistic action when combination sorafenib with
GdCl3.
Effects on hepatic histopathological changes
In the liver, there was normal lobular architecture, with
the central vein and radiating hepatic cords in the livers
of control rat (Fig. 1a). In the 4 week DMN group, the
liver sections revealed collagen fiber deposition, marked
cirrhosis, and severe centrilobular necrosis. We observed
marked reduction in the thickening of the collagen bun-
dles in the combination treatment (S + G) group.
Liver fibrosis was quantitatively assessed by morpho-
metric examination of liver sections incubated with 0.1 %
Sirius red, which specifically stains collagen. Little collagen
was present in normal liver, except around the small
central venous walls (Fig. 1b). In contrast, the livers
of rats treated for 4 weeks with DMN showed marked
distortion of architecture, including portal and lobular
bridging fibrosis, cirrhotic nodule formation, and thick-
ened reticulum fibers joining the central areas. Treatment
of DMN-treated rats with sorafenib plus GdCl3 signifi-
cantly decreased liver fibrosis (Fig. 1b and c).
Changes in Hyp content in the liver are considered an
index of collagen metabolism and provide valuable infor-
mation about the biochemistry and pathology of liver
fibrosis. Rats treated with DMN showed a significant,
3.2-fold increase in Hyp content, expressed as μg/g of
liver tissue (p < 0.01), compared with control rats (Fig. 1d),
a finding consistent with the marked cirrhosis and ac-
cumulation of collagen bundles in the liver observed
on histopathological examination. Treatment of rats
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with sorafenib or GdCl3 slightly reduced the Hyp content
in liver (p > 0.05), whereas treatment with both resulted in
a significant decrease (p < 0.05) in liver Hyp, suggesting
that combination therapy ameliorated hepatic collagen
deposition in DMN-induced liver injury.
Effect of sorafenib plus GdCl3 on hepatic angiogenesis-
related factors
Aberrant angiogenesis has been implicated in the pro-
gression of hepatic fibrosis and is considered a major de-
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Fig. 1 Effects of sorafenib and/or GdCl3 on histological changes of rat livers. a Histological images of rat livers stained with HE (magnification X200).
b Histological images of rat livers stained with Sirius red (magnification X100). c qualification of Fig. 1b. d Liver Hyp content. The number in HE, Sirius
red staining, and Hyp detection was as the same as the animal number in each group. All results are expressed as mean ± S.D. *, p < 0.05; ** p < 0.01 vs
4 W. Control, vehicle alone; 4 W, DMN for 4 weeks; S, DMN for 4 weeks plus sorafenib for 2 weeks; G, DMN for 4 weeks plus GdCl3 for 2 weeks; S + G,
DMN for 4 weeks plus sorafenib and GdCl3 for 2 weeks
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cirrhosis [21]. Incubation of tissue sections with anti-
body to vWF showed very weak staining in control rats,
whereas rats treated with DMN for 4 weeks showed an
irregular vascular pattern in the portal/periportal areas
of the expanding portal tracts. Treatment with sorafenib
alone inhibited vessel formation in portal and periportal
areas, whereas GdCl3 alone did not markedly inhibit
vWF expression. The combination of sorafenib plus
GdCl3 significantly reduced vWF expression, indicating
that this inhibitory effect was due to sorafenib. Real-time
RT-PCR showed that treatment with DMN for 4 weeks
increased CD31 mRNA expression about 7-fold compared
with control rats. Sorafenib treatment of DMN-treated
rats significantly reduced CD31 mRNA expression
compared with rats treated with DMN (p < 0.01), whereas
GdCl3 had little effect on CD31 mRNA expression
(Fig. 2b). Sorafenib plus GdCl3 significantly reduced
CD31 mRNA expression.
Treatment with DMN significantly enhanced the ex-
pression of VEGF, Ang1 and VCAM1 mRNAs compared
with control rats, with sorafenib treatment ameliorating
these effects and GdCl3 having a slight effect. Sorafenib
plus GdCl3 reduced the expression of VEGF, Ang1 and
VCAM1 mRNAs significantly compared with DMN-
treated rats.
Western blotting with antibodies to CD31, VEGF, Ang 1
and VCAM yielded similar results (Fig. 2c). Taken together,
these results showed that liver SECs were important for
DMN-induced liver fibrosis. The effects of sorafenib plus
GdCl3 on angiogenesis and related factors were likely due
to sorafenib, with GdCl3 having little effect.
Sorafenib plus GdCl3 inhibits proinflammatory cytokines
KCs synthesize a variety of mediators, such as proin-
flammatory cytokines, chemokines, leukotrienes and re-
active oxygen species (ROS), fulfilling a crucial role in
immune responses in the liver [22]. KCs inhibition has
been shown to protect against hepatic injury, including
ischemia/reperfusion injury, alcohol-induced injury, and
injuries induced by certain toxicants, such as cyclohexi-
mide [23]. While low levels of CD68-positive KCs were
present in hepatic sinusoids of control livers, DMN
treatment for 4 weeks enhanced the numbers of KCs
strongly positive for CD68 in hepatic sinusoids, as well
as in portal areas and areas adjacent to fibrotic septa
(Fig. 3a). Although sorafenib treatment did not reduce
CD68 expression, GdCl3 inhibited CD68 expression
significantly. Similarly, real-time RT-PCR showed that
DMN treatment upregulated CD68 mRNA expression
about 8.8-fold (Fig. 3b); again, although sorafenib had lit-
tle effect on CD68 mRNA level, GdCl3 reduced CD68
mRNA expression significantly, as did the combination
of sorafenib plus GdCl3. Western blotting for CD68 pro-
tein yielded similar results (Fig. 3c).
TNF-α, IL-1β and CCL2 are mainly derived from KCs
after liver injury. Real-time RT-PCR showed that 4 weeks
of treatment with DMN increased TNF-α mRNA ex-
pression about 40-fold (p < 0.01) (Fig. 3b). Although so-
rafenib alone had little effect on TNF-α mRNA level, the
combination of sorafenib plus GdCl3 markedly reduced
TNF-α mRNA. These findings were further confirmed
by western blotting (Fig. 3c).
Taken together, these results showed that KCs were
activated during DMN-induced liver fibrosis. Although
sorafenib alone could not significantly inhibit KC activa-
tion or the production of proinflammatory cytokines,
the combination of sorafenib plus GdCl3 suppressed
these proinflammatory responses.
Effect of sorafenib plus GdCl3 on hepatic pro-fibrotic
factor expression
Sustained deposition of extracellular matrix mainly re-
sults from the activation of HSCs. We therefore assessed
the correlation between collagen accumulation and HSC
activation by analyzing the expression of α-SMA, a
marker of activated HSCs, in liver sections. Although
only vascular smooth muscle cells were positive for α-
SMA in control rats, the number of α-SMA-positive
HSCs was markedly increased after 4 weeks of treatment
with DMN (Fig. 4a). Either sorafenib or GdCl3 alone
decreased α-SMA expression, findings confirmed by
real-time RT-PCR and western blotting (Fig. 4b).
The expression levels of TGF-β1, TIMP-1 and Col1
(α1) were markedly higher in DMN-treated than in con-
trol rats. The sorafenib or GdCl3 alone could inhibit
these profibrotic factor to some extent (there were no
significant) the combination of sorafenib plus GdCl3
markedly reduced their expression.
Taken together, these results confirm that DMN activates
HSCs and induces the accumulation of extracellular
matrix, which may facilitate or result in liver fibrosis. The
combination of sorafenib plus GdCl3 significantly inhibited
HSC activation and reduced liver fibrosis development.
Effects of sorafenib plus GdCl3 on interactions of HSC, KC,
and SEC
The pathophysiological involvement of HSCs, KCs, and
LSECs in DMN-induced liver fibrosis was investigated
by immunochemically assessing the co-localization of α-
SMA, CD68, and vWF by confocal microscopy. Tricolor
immunofluorescence staining of liver sections from rats
treated for 4 weeks with DMN showed CD68+ KCs near
or directly adhering to α-SMA+ HSCs in the sinusoids
and portal areas (Fig. 5). Sorafenib markedly reduced
vWF expression, whereas GdCl3 reduced CD68 expres-
sion and the interactions of HSCs and KCs. These re-
sults collectively demonstrated that sorafenib combined
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with GdCl3 inhibited interactions among HSCs, SECs
and KCs, cells that play key roles in liver fibrosis.
Discussion
Angiogenesis and inflammation play important roles in
the development of liver fibrosis, making them potential
therapeutic targets. Since the anti-fibrotic effects of so-
rafenib and GdCl3 in the progression of liver fibrosis are
unclear, we assessed the in vivo therapeutic effects of
this combination in DMN-induced liver fibrosis. We
found that sorafenib plus GdCl3 achieved effects super-
ior to those of either agent alone, improving liver func-
tion and reducing hydroxyproline content. Furthermore,
this combination treatment was simultaneously directed



























































Control 4W S G S+G
C
2
Control 4W S G S+G
V
3



































Control  4W   S    G   S+G
36kD
Fig. 2 Effect of sorafenib and/or GdCl3 blockage on angiogenesis in DMN-induced liver fibrosis in vivo. a vWF immunohistochemistry (magnification
X400, n = 4). b Levels of mRNAs encoded by genes related to angiogenesis (n = 6). c the Expression of CD31, VEGF, Ang1, VCAM1 was analyzed using
western blot (n = 6). Control, vehicle alone; 4 W, DMN for 4 weeks; S, DMN for 4 weeks plus sorafenib for 2 weeks; G, DMN for 4 weeks plus GdCl3 for
2 weeks; S + G, DMN for 4 weeks plus sorafenib and GdCl3 for 2 weeks. The negative control consisted of samples from DMN-treated animals in the
absence of primary antibody. All results reported as mean ± S.D. *p < 0.05; **p < 0.01 vs 4 W
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Advanced fibrosis and cirrhosis represent the main
pathophysiological consequences of chronic liver dis-
ease and can lead to life-threatening clinical sequelae
[24]. The major mechanisms underlying progressive
scarring of the liver (fibrogenesis) have been explored
and consolidated in the past few years [1, 3]. Since
many cell types are involved in liver fibrosis, includ-
ing HSCs, SECs and KCs, targeting only one cell type
may be insufficient [25].
Angiogenesis is a basic change occurring during repair
by granulation tissue [26] and is a hypoxia-stimulated,
growth factor-dependent process involving the formation
of new vascular structures from pre-existing blood vessels
[27]. Hepatocellular hypoxia and angiogenesis have been
found to accompany fibrogenesis after liver injury, with
hypoxia contributing directly to the fibrosis progression
[28]. Following CCl4-induced liver injury in mice, anti-
angiogenic agents have been found to ameliorate fibrosis
a
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Fig. 3 Effects of sorafenib and/or GdCl3 blockage on in vivo expression of proinflammatory cytokines in liver fibrosis. a CD68 immunohistochemistry
(magnification X 400, n = 4). b Levels of mRNA encoded by genes encoding proinflammatory cytokines in rats with DMN-induced fibrosis
(n = 6). c The Expression of CD68, TNF-α, IL1β, CCL2 was analyzed using western blot (n= 6). Control, vehicle alone; 4 W, DMN for 4 weeks; S, DMN
for 4 weeks plus sorafenib for 2 weeks; G, DMN for 4 weeks plus GdCl3 for 2 weeks; S + G, DMN for 4 weeks plus sorafenib and GdCl3 for 2 weeks. Results
reported as mean ± S.D. *p< 0.05; **p< 0.01 vs 4 W
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and improve survival by promoting parenchymal liver re-
generation [29]. However, antiangiogenic therapy, consist-
ing of pharmacological inhibition of integrins αvβ3, was
found to promote fibrosis progression, both in experimen-
tal biliary (portal) and panlobular hepatic fibrosis [13].
Nevertheless, integrin inhibition had antifibrotic effects on
isolated HSCs, which up-regulate this receptor upon activa-
tion. Although we found that sorafenib alone significantly
inhibited the increases in vWF, CD31, VEGF, Ang1 and
VACM1 expression observed in DMN-induced liver fibro-
sis, sorafenib could not decrease significantly Col1 (α1) ex-
pression or Hyp content. This is not consistent with others
[30]. Such a difference may be due to the fact that the dose
of sorafenib used here is low. On the other hand, only re-
duction on angiogenesis, one important factor in liver fibro-
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Fig. 4 Effects of sorafenib and/or GdCl3 on in vivo expression of pro-fibrotic factors in rat liver fibrosis. a α-SMA immunohistochemistry (magnification X
200, n= 4). b Levels of mRNA encoded by genes encoding factors associated with fibrosis sis (n= 6). c the Expression of α-SMA, TIMP1, TGF-β1, COL1 was
analyzed using western blot (n= 6). Control, vehicle alone; 4 W, DMN for 4 weeks; S, DMN for 4 weeks plus sorafenib for 2 weeks; G, DMN for 4 weeks plus
GdCl3 for 2 weeks; S + G, DMN for 4 weeks plus sorafenib and GdCl3 for 2 weeks. Results reported as mean ± S.D. * p< 0.05; ** p< 0.01 vs 4 W
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Meanwhile these results indicating that other pathological
factor, such as pro-inflammatory and pro-fibrotic also play
a key role in liver fibrosis.
Previously we reported that KCs are associated with
apoptosis, inflammation and fibrosis [20]. The role of
macrophages in the pathogenesis of liver fibrosis has
been investigated using specific KC blocking agents such
as GdCl3. Surprisingly, although we found that GdCl3
inhibited KC activation and the expression of pro-
inflammatory cytokines, it did not improve liver function
or liver Hyp content significantly, in contrast to previous
findings [14]. Since liver fibrosis arises from the inter-
action of many pathological factors, inhibiting KC
activation alone was not enough to suppress liver
fibrosis development; for example, GdCl3 had not sig-
nificantly effect on the expression of angiogenic-
associated factors, such as vWF, CD31, and VCAM.
Furthermore, GdCl3 has been found to enhance
macrophage activation and the expression of pro-
inflammatory cytokines in the lung. Based on these
reasons, we could conclude that GdCl3 has very lim-
ited effect on liver fibrosis [16].
Fig. 5 Effects of sorafenib and/or GdCl3 on interactions of HSCs, KCs and SECs in DMN-induced liver fibrosis in rats. Hepatic cryosections were stained
with antibodies against α-SMA (blue), CD68 (red), and vWF (green) (magnification X400, n = 3). 4 W, DMN for 4 weeks; S, DMN for 4 weeks plus sorafenib
for 2 weeks; G, DMN for 4 weeks plus GdCl3 for 2 weeks; S + G, DMN for 4 weeks plus sorafenib and GdCl3 for 2 weeks
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Liver fibrosis is believed to be reversible through
the apoptosis of activated HSCs and the degradation
of ECM proteins [23]. Treatment with sorafenib has
been found to reduce portal pressure and angiogenesis in
DMN- and BDL-treated rats [32]. In addition, sorafenib
was found to inhibit the proliferation of various tumor
cells and to induce their apoptosis by targeting the tyro-
sine kinase associated with PDGFR-β [33, 34]. In addition,
the induction of apoptosis was found to be accompanied
by the down-regulation of cyclins and Cdks in HSCs [35].
In contrast, other studies reported that sorafenib could
not improve liver fibrosis in rats [13, 36]. Taken together,
these results suggest that sorafenib has limited effects
on liver fibrosis.
Understanding of the pathogenesis of human liver
fibrosis has progressed significantly over the past 10–15
years [37, 38]. Indeed, the in vivo microenvironment is im-
portant in regulating HSC activation and function. In this
complex environment, KCs and liver SECs modulate in-
flammation and angiogenesis during the development of
liver fibrosis. KCs produce TNF-α, while liver SECs secrete
VEGF, activating HSCs. These cells produce ECM pro-
teins, particularly collagen I, thus contributing to hepatic
injury. The combination of two fibrosis inhibitors may be
superior to each alone [39]. The mechanism of combin-
ation treatment in DMN-treated liver fibrosis should be
further investigated.
In summary, the data presented in the present study
demonstrates that sorafenib significantly inhibited angio-
genesis and related factors, and that GdCl3 reduced KC
activation and inhibited proinflammatory cytokines. The
combination of sorafenib plus GdCl3 may significantly hep-
atic fibrosis by inhibiting angiogenesis, proinflammatory
cytokines, and the interactions of HSCs, SECs and KCs.
Conclusion
Sorafenib plus GdCl3 can suppress collagen accumulation,
suggesting that this combination may be a potential
therapeutic strategy in the treatment of liver fibrosis.
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